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a  b  s  t  r  a  c  t
Background  and  purpose:  Percutaneous  cardiopulmonary  support  (PCPS)  is useful  in  the rescue  of  patients
who have  experienced  severe  cardiogenic  shock.  We  investigated  the  predictive  factors  of survival  among
patients with  cardiogenic  shock  requiring  PCPS.
Methods and  subjects:  We  enrolled  29  patients  (21  men  and  8 women,  73  ±  10 years  old)  with  circulatory
collapse  complicating  acute  myocardial  infarction  (AMI)  requiring  PCPS.  Fifteen  patients  could  be weaned
from PCPS  and  survived  for more  than  1 month  (group  A), while  the  other  14  patients  could  not  (group  B).
We investigated  the  initial  PCPS  settings,  and  performed  the  appropriate  laboratory  tests.  Hemodynamic
data  and  arterial  base  excess  (BE)  values  were  recorded  throughout  the  PCPS  treatment.
Results:  There  was  no difference  in  the  laboratory  test  results  or the  left ventricular  ejection  fraction
between  the groups  at the  start  of PCPS.  PCPS  ﬂow  (l/min)  was  signiﬁcantly  lower  in  group  A than  in
group  B at  the  24th  hour  of  PCPS  (2.26  ±  0.36  and  2.54  ±  0.41,  respectively).  There  were  no differences  in
blood pressure  between  the  groups.  During  the  24-h  period  prior  to the  end  of  PCPS, BE  remained  almost
normal  in  group  A. In group  B, BE  decreased  continuously  throughout  the  same  period.  BE  values  were
signiﬁcantly  lower  compared  to  those  obtained  in group  A  12 h  prior  to the end of  PCPS.
Conclusions:  A  reduction  in  PCPS  ﬂow  without  hemodynamic  collapse  may  allow  for successful  weaning
otent
2  Japfrom  PCPS.  BE  may  be  a p
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Recent advances in reperfusion strategies for acute myocar-
ial infarction (AMI) have raised the survival rate [1,2]. However,
atients with cardiogenic shock complicating AMI  are still difﬁcult
o treat and have poor in-hospital outcomes [3–9]. Percutaneous
ardiopulmonary support (PCPS) has been employed for severe
ardiogenic shock complicating AMI  as well as for other cases
f circulatory collapse caused by severe heart failure, fulmi-
ant myocarditis, and refractory ventricular arrhythmia [9–19].
lthough PCPS devices including a circuit, pump, and cannula-
ion sheath have been developed, clinical complications such as
leeding, infection, platelet depletion, lung edema, left ventricular
fterload, and limb ischemia continue to plague patients [20,21].
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Weaning from PCPS is often difﬁcult and not always successful
due to the complications mentioned above, and therefore, the
appropriate discontinuation of PCPS is a critical problem [22,23].
Several reports found that appropriate adjustment of the support
ﬂow rate after the initiation of PCPS facilitates the recovery of
cardiac function and subsequently contributes to prevent the com-
plications associated with PCPS [24–27].  To date, there have been
no guidelines established for the use of PCPS, nor have methods
been established for successful weaning from PCPS. To explore the
predictive factors for successful weaning from PCPS, we retrospec-
tively reviewed patients who  had required PCPS for cardiogenic
shock complicating AMI.
Materials and methods
Study populationWe  retrospectively reviewed the patients treated with
PCPS between January 2006 and December 2008. Twenty-nine
consecutive patients (21 men  and 8 women, 73 ± 10 years old) in
vier Ltd. All rights reserved.




















































Fig. 1. Study protocol and data collection. At the start of PCPS, laboratory tests
listed in Table 2. BE levels at the start of PCPS were extremely low
in both groups, which indicated the disturbance of peripheral per-
fusion. BE in both groups improved, but at 72 h of PCPS treatment,
Table 1
Baseline characteristics of the 29 patients included.
Group A Group B p-Value
Age 73 ± 11 73 ± 10 0.33
Gender, male (%) 80.0 64.2 0.33
Alb,  g/dl 3.2 ± 0.6 2.9 ± 0.6 0.25
Bil,  mg/dl 1.2 ± 1.1 0.9 ± 0.6 0.16
Cre,  mg/dl 1.5 ± 0.5 1.9 ± 0.7 0.23
LVEF, % 35 ± 15 32 ± 9 0.39
Peak CK, IU/L 8,108 ± 4,999 10,650 ± 5,769 0.09
Peak CK-MB, IU/L 525 ± 375 674 ± 544 0.15
Infarct-related artery
LMT/LAD/RCA/LCx, % 27/27/33/13 43/50/0/7 0.31
Number of diseased vessels 1.7 ± 0.8 1.9 ± 0.7 0.33
Past  history of OMI 5 3 0.47
LVAS implantation 0 4 0.02D. Morisawa et al. / Journal 
hom PCPS was used for cardiogenic shock complicating AMI, were
nrolled in this study. All 29 patients underwent emergent per-
utaneous coronary interventions (PCI) and subsequent successful
evascularization. Among those patients, 15 could be successfully
eaned from PCPS and survived for more than 1 month (group
), while the other 14 patients (group B) could not be successfully
eaned from PCPS. Group B included 9 patients who  died with
reatment of PCPS and 4 patients who were implanted with a left
entricular assist system (LVAS) because they could not be weaned
rom PCPS and one patient who died due to prolonged low output
yndrome 17 days after the discontinuation of PCPS.
mergent coronary angiography, PCI, and PCPS
Emergent coronary angiography (CAG) and PCI were performed
ith a 7-Fr. guide catheter via the femoral approach. Intra-aortic
alloon pumping (IABP) and PCPS were initiated in the catheter
aboratory. IABP was employed to treat all cases in this study
opulation. The indication and the timing of PCPS initiation were
etermined by the experienced interventional cardiologists in
harge, according to the following criteria: severe cardiogenic
hock refractory to the administration of catecholamine and IABP
fter the correction of hypovolemia, hypoxemia, and acidemia.
CPS system
We  use a heparin-coated PCPS circuit system (CAPIOX, Terumo
nc., Tokyo, Japan) comprising a hollow-ﬁber microporous mem-
rane oxygenator, a heat exchanger, a centrifugal pump, and
annulae. Venous drainage was performed using a 19-Fr. venous
annula inserted in the femoral vein, and the tip of the tube was
laced in the right atrium. Oxygenated blood was returned by a
7-Fr. arterial cannula.
CPS management
The initial ﬂow rate of PCPS was 3.0–3.5 l/min. This value was
hosen to stabilize the hemodynamic disturbance, and subsequent
CPS ﬂow was adjusted as soon as possible in accordance with the
evel of cardiac function, the patient’s blood pressure and the state
f the systemic circulation. To prevent circulatory disturbances in
he legs, arterial cannulation of the PCPS and of the distal superﬁcial
emoral artery was performed using a 4-Fr. sheath bypass imme-
iately after starting PCPS. An intra-arterial monitor was  always
nserted into the right radial artery. A Swan-Gantz catheter was
sed to continuously monitor hemodynamics. Activated clotting
ime was controlled to be 180 ± 20 s throughout PCPS treatment
ith the combined administration of nafamostat mesilate and hep-
rin.
ata collection
We  recorded the initial PCPS settings, laboratory test results, and
eft ventricular ejection fraction (EF) as determined by echocardiog-
aphy just after the start of PCPS. Hemodynamic data and arterial
ase excess (BE) were measured throughout the PCPS treatment.
e compared those data between the groups at the 24th, 48th,
nd 72nd hour of PCPS treatment, and at every 6–12 h during the
nal 24 h of PCPS treatment (Fig. 1). As previously described, group
 included 9 patients who died with PCPS treatment. The time of the
nd of PCPS was identical to the time of death for those 9 patients.tatistical analysis
All data are expressed as the mean ± S.D. All statistical analy-
es were performed using Stat View5.0 software (Abacus Conceptsand echocardiography were performed. PCPS ﬂow, hemodynamic parameters and
base excess were recorded at the points marked with arrows. PCPS, percutaneous
cardiopulmonary support; BP, blood pressure.
Inc., Berkeley, CA, USA). Comparisons were analyzed by one-way
ANOVA. A value of p < 0.05 was considered to be statistically signif-
icant.
Results
The baseline characteristics of this study population are sum-
marized in Table 1. There were no signiﬁcant differences between
the groups with respect to laboratory data, cardiac function as rep-
resented by EF, the distribution of the infarct-related artery, the
number of diseased vessels, or the number of patients who  had
past history of old myocardial infarction. The elapsed time from the
onset of AMI  to the start of PCI in group A (88 ± 66 min) was  similar
to that in group B (83 ± 62 min, p = 0.45). Group A included no cases
of asystole nor pulseless electrical activity (PEA) and 6 patients with
ventricular ﬁbrillation (VF) at the start of PCPS, whereas, group
B included one patient with asystole, 2 patients with PEA, and 3
patients with VF at the start of PCPS.
PCPS management for the initial 72 h
The duration of PCPS treatment in group B was  longer than that
in group A, but this difference was not signiﬁcant (Table 2). The
serial changes in BE, mixed venous oxygen saturation (SvO2), and
catecholamine dose (total dose of dopamine and dobutamine) areData are presented as the mean value ± S.D. or the number (%) of subjects.
LMT, left main trunk; LAD, left anterior descending coronary artery; RCA, right
coronary artery; LCx, left circumﬂex coronary artery; LVEF, left ventricular ejection
fraction; Alb, serum albumin; Bil, serum total bilirubin.
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Table  2
Hemodynamic data, base excess, and catecholamine dose for PCPS management.
Group A Group B p-Value
Duration of PCPS, h 58 ± 38 98 ± 63 0.06
(median, range) 44, 14–127 88, 55–203
At the start of PCPS
BE, mequiv/L −10.6 ± 8.1 −9.3 ± 8.6 0.48
PCPS ﬂow, l/min 2.79 ± 0.43 2.88 ± 0.39 0.31
Catecholamine, /kg/min 9.4 ± 5.5 7.0 ± 3.3 0.12
At  the24th hour of PCPS, n n = 10 n = 10
BE,  mequiv/L −0.17 ± 1.8 −2.5 ± 3.7 0.092
SvO2, % 64 ± 10 71 ± 17 0.19
PCPS ﬂow, l/min 2.26 ± 0.36 2.54 ± 0.41 0.038
HR,  /min 94 ± 19 99 ± 18 0.27
Peak BP, mmHg 118 ± 17 113 ± 23 0.32
Catecholamine, g/kg/min 7.8 ± 4.9 12.0 ± 7.4 0.093
At  the 48th hour of PCPS, n n = 7 n = 9
BE,  mequiv/L 0.91 ± 0.62 −3.1 ± 6.3 0.059
SvO2, % 67 ± 10 74 ± 28 0.49
PCPS ﬂow, l/min 2.21 ± 0.30 2.57 ± 0.48 0.047
HR,  /min 104 ± 12 105 ± 23 0.45
Catecholamine, g/kg/min 11.0 ± 9.6 13.0 ± 8.3 0.34
At  the 72nd hour of PCPS, n n = 5 n = 9
BE,  mequiv/L 1.92 ± 1.34 −2.35 ± 4.6 0.035
SvO2, % 68 ± 10 74 ± 25 0.49
PCPS ﬂow, l/min 2.06 ± 0.40 2.68 ± 0.33 0.0056
HR,  /min 106 ± 17 106 ± 20 0.49
Catecholamine, g/kg/min 6.4 ± 3.8 10.5 ± 5.5 0.085






















Fig. 3. PCPS ﬂow in PCPS management. PCPS ﬂow (l/min) at the 24th, 48th, and
−0.02 ± 2.12 mequiv/L, respectively). In group B, BE improved at
24 h prior to the termination of PCPS (−2.8 ± 6.6 mequiv/L). The
values were similar to those obtained at the same time-point
in group A. BE deteriorated continuously throughout this 24-h
Table 3CPS, percutaneous cardiopulmonary support; HR, heart rate; BE, base excess; SvO2,
ixed venous oxygen saturation; BP, blood pressure.
E in group B was signiﬁcantly lower than that in group A. There
ere no differences in systemic peak blood pressure between the
wo groups at the 24th hour and at the 48th hour of PCPS treat-
ent (Fig. 2). At the 72nd hour of PCPS treatment, peak blood
ressure was higher in group A than in group B (Fig. 2). The PCPS
ow required to maintain hemodynamics was signiﬁcantly lower in
roup A than in group B at each time of PCPS (Fig. 3). There included
 patients in group B who could not drain enough volume of venous
lood to continue PCPS treatment, because of hypovolemia, fatal
leeding, and inappropriate location of venous cannula. There were
o differences in the catecholamine dose received to maintain
lood pressure between the groups. These ﬁndings suggested that
he patients, in whom PCPS ﬂow could be reduced without the dis-
urbance of hemodynamics within 24 h after the start of PCPS, were
uccessfully weaned from PCPS.
ig. 2. Blood pressure in PCPS management. Blood pressure (mmHg) at the 24th,
8th, and 72nd hour of PCPS treatment. Solid bars represent blood pressure in group
,  and empty bars represent blood pressure in group B. *p < 0.05. PCPS, percutaneous
ardiopulmonary support; BP, blood pressure.72nd hour of PCPS treatment. Solid bars represent PCPS ﬂow in group A, and empty
bars represent PCPS ﬂow in group B. *p < 0.05. PCPS, percutaneous cardiopulmonary
support.
PCPS termination
To explore the prognostic factor for the termination of PCPS, we
reviewed the hemodynamic data and BE during the 24-h period
prior to the termination of PCPS (Table 3 and Fig. 4). Systemic blood
pressure was higher and PCPS ﬂow was  lower in group A compared
to group B, which indicates that the trends observed during the ini-
tial 24–48 h of PCPS treatment continued until the end. The serial
changes in BE prior to the termination of PCPS at 24, 12, and 6 h
prior to the termination of PCPS are shown in Fig. 4. As previously
mentioned, BE levels were quite low and similar in both groups at
the start of PCPS. In group A, BE improved and remained almost
normal until the termination of PCPS (−0.82 ± 2.55, −0.31 ± 1.93,Hemodynamic data, base excess, and catecholamine dose during the 24-h period
prior to the end of PCPS.
Group A Group B p-Value
24 h prior to the end of PCPS, n n = 12 n = 14
SvO2, % 53 ± 9.2 67 ± 14 0.13
HR,  /min 107 ± 19 97 ± 18 0.19
Peak BP, mmHg  126 ± 13 102 ± 26 0.0059
PCPS ﬂow, l/min 2.23 ± 0.46 2.63 ± 0.42 0.028
BE  −0.82 ± 2.55 −2.8 ± 6.6 0.19
Catecholamine, g/kg/min 7.0 ± 3.6 9.6 ± 4.4 0.059
12  h prior to the end of PCPS, n n = 13 n = 15
SvO2, % 65 ± 18 65 ± 17 0.49
HR,  /min 100 ± 21 98 ± 12 0.44
Peak BP, mmHg  121 ± 15 98 ± 24 0.0096
PCPS ﬂow, l/min 2.15 ± 0.27 2.39 ± 0.82 0.16
BE  −0.31 ± 1.93 −4.4 ± 7.8 0.044
Catecholamine, g/kg/min 5.9 ± 3.6 11.0 ± 7.5 0.016
6  h prior to the end of PCPS, n n = 13 n = 17
SvO2, % 70 ± 12 64 ± 17 0.27
HR,  /min 103 ± 18 98 ± 23 0.19
Peak BP, mmHg  123 ± 32 87 ± 33 0.0037
PCPS ﬂow, l/min 1.96 ± 0.23 2.48 ± 0.59 0.0065
BE  −0.02 ± 2.12 −7.1 ± 10.0 0.0074
Catecholamine, g/kg/min 5.5 ± 3.5 11.7 ± 8.0 0.0063
Data are presented as the mean value ± S.D. or the number of subjects.
PCPS, percutaneous cardiopulmonary support; HR, heart rate; BE, base excess; SvO2,
mixed venous oxygen saturation; BP, blood pressure.
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bhe serial changes in BE during the 24-h period prior to the termination of PCPS
re  shown. Triangles represent BE in group A, and squares represent BE in group B.
p  < 0.05. BE, base excess; PCPS, percutaneous cardiopulmonary support.
indow (−4.4 ± 7.8 mequiv/L at 12 h prior to the termination of
reatment, and −7.1 ± 10.0 mequiv/L at 6 h prior to the termina-
ion), a signiﬁcant difference between the groups emerged at 12 h
rior to the termination of PCPS (p < 0.05). These ﬁndings indicated
hat the prognosis may  be poor if BE was dropping precipitously in
ssociation with systemic hypotension and a high PCPS ﬂow rate.
The causes of death in group B were low cardiac output
yndrome (6 patients), multiple organ failure (2 patients), cere-
rovascular accident (1 patient), and sepsis (1 patient). The
omplications associated with PCPS were severe limb ischemia
n PCPS-inserted limb (5 patients), bleeding (4 patients), platelet
epletion (5 patients), and pneumonia (1 patient).
iscussion
It has been reported that the survival of patients with severe car-
iogenic shock complicating AMI  could be improved by early PCI
nd the appropriate use of circulatory assist devices including PCPS
9,14,18,23]. PCI must be performed in that situation, the progno-
is remains poor unless the state of shock can be improved. In the
resent study, the number of patients that survived for more than 1
onth was 19 including 4 patients that underwent LVAS implanta-
ion, the survival rate (65.5%) was consistent with previous reports
18,22]. We  demonstrated that patients who could be weaned from
CPS required a lower ﬂow rate of PCPS support to maintain sys-
emic circulation at the 24th hour of PCPS treatment. Oshima et al.
eported that the PCPS ﬂow was reduced 72 h after the initiation
f PCPS in patients who could be successfully weaned from PCPS
27]. Their study enrolled patients who experienced severe car-
iac failure due to various causes, including postcardiac surgery,
ulmonary thrombosis, AMI, and acute myocarditis. In our study
opulation consisting of patients with AMI, the early reduction of
CPS ﬂow was considered to be important to decrease the afterload
nd to improve the coronary circulation. Several reports advocated
he fundamental concept that the lowest rate of ﬂow that did not
nduce peripheral circulatory failure should be used and adjusted
n accordance with cardiac function after the initial stabilization
stablished by installation of PCPS [24,26,27].  The present PCPS
tudy is consistent with previous reports.
We  concluded that the deterioration of BE during PCPS treat-
ent may  be a potent factor in predicting a poor prognosis. A low
E indicates metabolic acidosis, and is usually caused by the dis-
urbance of peripheral circulation, renal failure, and lactic acidosis.
he deterioration of BE at the start of PCPS in both groups may  have
een caused by the disturbance of peripheral circulation, therefore,diology 60 (2012) 350–354 353
BE levels improved after the start of PCPS even in group B. Serum
lactate level is considered a prognostic indicator for patients with
cardiogenic shock requiring PCPS, and the increase in serum lactate
level is caused by the tissue hypoxia, sepsis, hepatic dysfunction,
and multiple organ failure [26,27].  It is possible that lactic acidosis
may  have occurred in group B during the treatment of PCPS, and BE
deteriorated again before the discontinuation of PCPS.
If PCPS cannot be terminated without inducing complications
(signs of severe brain injury or other organ failure), LVAS may  be
required. We  included 4 patients who subsequently underwent
LVAS implantation in group B, who did not exhibit severe com-
plications of PCPS or BE deterioration (1.6 ± 3.2 mequiv/L at both
12 h and 6 h prior to the termination of PCPS). The timing of LVAS
implantation is still controversial, but it is important to determine
whether cardiac function would recover with medical and mechan-
ical support, including IABP and PCPS [23,28].
Study limitations
This was  a retrospective observational study with a relatively
small population and was  not a randomized controlled study.
Another limitation was that the dose of medicinal therapy (includ-
ing catecholamine, a vasodilator, diuretics, sodium bicarbonate,
and other pharmacological agents) differed among patients. In gen-
eral, a high dose of catecholamine is often required during PCPS
treatment when blood pressure cannot be maintained. However,
high doses of catecholamine often disturb the peripheral circulation
and induce ischemic changes in digestive organs. In this study, the
average total dose of dopamine and dobutamine was similar in both
groups, but there might be a possibility that this pharmacological
therapy affected the results of this study.
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